Senior woman header
Senior woman header
Photo header of senior man
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND has launched the Syn-One Test™ to offer physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy. And our mission has just begun.

Learn More
Senior woman header
Senior woman header
Senior man header
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND has launched the Syn-One Test™ to offer physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy. And our mission has just begun.
Learn More

Introducing the Syn-One Test™ from CND Life Sciences

Offering physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy.

seal icon

CLIA-Certified Pathology Lab

test tube icon

Dedication to Science & Research

DNA icon

Patient-Focused Mission

microscope icon

Quality & Reliability at Our Core

Clarity and Confidence of Syn-One

Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.  

Learn More

Our Commitment to Patients

We did not invent the saying “knowledge is power,” but we subscribe to this philosophy as part of our mission. Patients and caregivers rely on physicians to make vital clinical judgments every day, and we are committed to providing reliable diagnostic technologies and useful insights that help optimize care.

Learn more about what drives us.

Learn More

Read our perspectives on the industry, the field of neurodiagnostics, patient care, and other topics.

Insights
November 2, 2021

Researchers Detect Alpha-Synuclein in Nerve Biopsy 6 Years Before Clinical Diagnosis of Dementia With Lewy Bodies

Dr. Todd Levine, CND Life Sciences’ Co-Founder and CMO, will speak at the product presentation…
Insights
October 5, 2021

CND Life Sciences’ Chief Medical Officer to Present at AANEM Annual Meeting

Dr. Todd Levine, CND Life Sciences’ Co-Founder and CMO, will speak at the product presentation…
Insights
September 21, 2021

Meet CND Life Sciences’ New Lab Director, Jimmie Evans, BS, MLS (ASCP)

Jimmie Evans always knew he wanted to work in healthcare. And when he needed some…
VIEW ALL INSIGHTS

Check out press releases, news alerts and coverage of CND happenings.

In the News
November 22, 2021

Phase 1b Results Reported for Potentially First-in-Class Parkinson’s Treatment

Boston-based biopharma company Yumanity Therapeutics announced last week that its drug candidate, YTX-7739, met its…
In the News
November 17, 2021

Monoclonal Antibody for Parkinson’s Disease Moves to Phase I Clinical Testing

A monoclonal antibody that binds to alpha-synuclein is advancing into a clinical trial after showing…
In the News
October 27, 2021

New Research Identifies Potential Pathway for Stopping Spread of Alpha-Synuclein

A hallmark of Parkinson’s disease is the presence of Lewy bodies—abnormal clumps of protein primarily…
VIEW ALL NEWS
CND CASE STUDIES

For Clinicians: Request a Syn-One Test™ Kit

The Syn-One Test provides objective pathological evidence to aid in the diagnosis of a synucleinopathy. Simply collect three small punch skin biopsies from your patient, send them to our CLIA-certified lab, and CND Life Sciences will provide important visual insights to support a diagnosis. If you are a clinician, click below to order a Syn-One Test Biopsy Kit.

Order a Kit